Prostate cancer (CaP) is the most common cancer among men in Slovenia. However, the current diagnostic algorithm using PSA (prostate specific antigen) and BX (prostate biopsy) has notable limitations, especially in the gray zone of PSA values (2–10 ng/mL). The aim of modern diagnostics is to improve test specificity and sensitivity, and to better identify clinically significant CaP G 7 (Gleason ≥ 7). Proteomics, the study of proteins, enables biomarker identification to improve patient selection for BX. In this study, we analyzed 83 patients undergoing MRI (magnetic resonance imaging)-targeted fusion TRUS (transrectal ultrasound) prostate BX and biomarker testing via the Olink Target 96 Oncology II panel. Several biomarkers showed statistically significant differences between histopathological groups: ITGAV, TRAIL, FGF-BP1 and MSLN, with the first three being the most promising for detecting clinically significant prostate cancer.
|